Strategies for transporting nanoparticles across the blood–brain barrier
The DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.
Abstract
Nanoparticles have been widely deployed for brain-targeted delivery. Drugs can be embedded either in a matrix or deposited on the surface of nanoparticles, and the whole particle can cross the BBB effectively and be targeted to specific parts of the body in a controllable manner.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Regulated portals of entry into the cell
Conner, S. D., & Schmid, S. L. (2003) · Nature · doi:10.1038/nature01451 · Cited by 3,805
Intranasal delivery to the central nervous system: Mechanisms and experimental considerations
Dhuria, S. V., Hanson, L. R., & Frey, W. H. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21924 · Cited by 1,239
Nanoparticulate systems for brain delivery of drugs.
Kreuter, J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00122-8 · Cited by 1,107
Lipid-Based Nanoparticles as Pharmaceutical Drug Carriers: From Concepts to Clinic
Puri, A., Loomis, K., Smith, B., Lee, J.-H., Yavlovich, A., Heldman, E., & Blumenthal, R. (2009) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v26.i6.10 · Cited by 1,069
Tumor-Selective Delivery of Macromolecular Drugs via the EPR Effect: Background and Future Prospects
Maeda, H. (2010) · Bioconjugate Chemistry · doi:10.1021/bc100070g · Cited by 998
Mechanisms of Cellular Uptake of Cell-Penetrating Peptides
Madani, F., Lindberg, S., Langel, Ü., Futaki, S., & Gräslund, A. (2011) · Journal of Biophysics · doi:10.1155/2011/414729 · Cited by 984
Nanoparticulate systems for brain delivery of drugs
Kreuter, J. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.015 · Cited by 958
Cell‐penetrating peptides: 20 years later, where do we stand?
Bechara, C., & Sagan, S. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.04.031 · Cited by 857
Cell-penetrating peptides: classes, origin, and current landscape
Milletti, F. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.03.002 · Cited by 813
Approaches to transport therapeutic drugs across the blood–brain barrier to treat brain diseases
Gabathuler, R. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.028 · Cited by 802
Research works printed but not linked: 8
- Weidle, 2015, Cancer Genomics Proteomics, 12, 167
- Schmid-Brunclik, 2008, Am. J. Physiol.: Regul., Integr. Comp. Physiol., 295, R864
- Hagg, 2006, J. Neurotrauma, 23, 264
- Kozler, 2012, Neuroendocrinol. Lett., 33, 782
- Piraux, 2015, J. Appl. Phys., 117
- Zheng, 2015, Int. J. Clin. Exp. Med., 8, 1658
- Nounou, 2014, Cancer Res., 74
- Maletinska, 2000, Cancer Res., 60, 2300
Cited by
Items 101–200 of 310
Wang, N., Sun, P., Lv, M., Tong, G., Jin, X., & Zhu, X. (2017) · Biomaterials Science · doi:10.1039/c7bm00133a · Cited by 37
Liu, Y., Ma, Y., Xu, J., Chen, Y., Xie, J., Yue, P., Zheng, Q., & Ming, Y. (2017) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2017.10.009 · Cited by 40
Moradi, F., & Dashti, N. (2022) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-021-02196-x · Cited by 40
Bertrand, L., Nair, M., & Toborek, M. J. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666160726113001 · Cited by 39
Nanoparticles for Diagnosis and Target Therapy in Pediatric Brain Cancers
Guido, C., Baldari, C., Maiorano, G., Mastronuzzi, A., Carai, A., Quintarelli, C., Angelis, B. D., Cortese, B., Gigli, G., & Palamà, I. E. (2022) · Diagnostics · doi:10.3390/diagnostics12010173 · Cited by 39
Current progress on microRNAs‐based therapeutics in neurodegenerative diseases
Pereira, P., Queiroz, J. A., Figueiras, A., & Sousa, F. (2017) · WIREs RNA · doi:10.1002/wrna.1409 · Cited by 33
“The invasive approaches are directed to CNS delivery, including intracerebroventricular infusion, intrathecal, convection-enhanced delivery, and the disruption methods of BBB integrity.(33,106,107,112) These approaches have a high risk of side effects (such as infection, edema, and neuron damage), as well as some draw…”
BackgroundMethodInfluentialIn VivoMRI of Functionalized Iron Oxide Nanoparticles for Brain Inflammation
Tang, T., Valenzuela, A. E., Petit, F., Chow, S. S. L., Leung, K. H., Gorin, F. A., Louie, A. Y., & Dhénain, M. (2018) · Contrast Media & Molecular Imaging · doi:10.1155/2018/3476476 · Cited by 35
“All nanoparticle-based agents face the challenge of penetrating the blood-brain barrier, and a number of methods described in the literature to overcome the BBB, such as the opening of tight junctions using osmotic pressure or ultrasound disruption, can effectively generate pores in the BBB that enable the entry of im…”
BackgroundNatural Polysaccharide Carriers in Brain Delivery: Challenge and Perspective
Curcio, M., Cirillo, G., Rouaen, J. R. C., Saletta, F., Nicoletta, F. P., Vittorio, O., & Iemma, F. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12121183 · Cited by 36
“The passive transport, an energy-independent process, involves the transfer of nanoparticles from the blood to the brain under a concentration gradient, whereas the active transport routes, involving the hydrolysis of adenosine triphosphate (ATP), include receptor- and carrier-mediated transport [20].”
BackgroundWould Antioxidant-Loaded Nanoparticles Present an Effective Treatment for Ischemic Stroke?
Poellmann, M. J., Bu, J., & Hong, S. (2018) · Nanomedicine · doi:10.2217/nnm-2018-0084 · Cited by 34
Gkountas, A. A., Polychronopoulos, N. D., Sofiadis, G. N., Karvelas, E. G., Spyrou, L. A., & Sarris, I. E. (2021) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2021.106477 · Cited by 37
Recent Trend of Ultrasound-Mediated Nanoparticle Delivery for Brain Imaging and Treatment
Jo, S., Sun, I., Ahn, C., Lee, S., & Kim, K. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c22803 · Cited by 35
Computational Modeling of Pharmaceuticals with an Emphasis on Crossing the Blood–Brain Barrier
Alves, P. A., Camargo, L. C., de Souza, G. M., Mortari, M. R., & Homem-de-Mello, M. (2025) · Pharmaceuticals · doi:10.3390/ph18020217 · Cited by 41
“Despite challenges in overcoming the BBB and ensuring the safety of nanocarriers, future developments are expected to expand the library of prodrugs and introduce novel approaches for binding BBB enhancers to other chemical entities, advancing the field of CNS drug delivery [109,116,117].”
Sun, M., Qin, F., Bu, Q., Zhao, Y., Yang, X., Zhang, D., & Cen, X. (2025) · MedComm · doi:10.1002/mco2.70386 · Cited by 46
Lowering serum lipids via PCSK9-targeting drugs: current advances and future perspectives
He, N.-Y., Li, Q., Wu, C., Ren, Z., Gao, Y., Pan, L.-H., Wang, M., Wen, H.-Y., Jiang, Z., Tang, Z., et al. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2016.134 · Cited by 38
Sun, L., Liu, D., Fu, D., Yue, T., Scharre, D., & Zhang, L. (2021) · Chemical Engineering Journal · doi:10.1016/j.cej.2020.126733 · Cited by 32
Moin, A., Rizvi, S. M. D., Hussain, T., Gowda, D. V., Subaiea, G. M., Elsayed, M. M. A., Ansari, M., Alanazi, A. S., & Yadav, V. K. (2021) · Life · doi:10.3390/life11050421 · Cited by 32
“liposomes may cause its extrusion [76,113,114].”
Interactions between nanoparticles and pathological changes of vascular in Alzheimer’s disease
Lei, T., Yang, Z., Li, H., Qin, M., & Gao, H. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115219 · Cited by 36
Discerning the Role of Blood Brain Barrier Dysfunction in Alzheimer’s Disease
Tao, Q., Lin, R.-R., Chen, Y.-H., & Wu, Z. (2022) · Aging and Disease · doi:10.14336/ad.2022.0130-1 · Cited by 38
“Under physiological conditions, TJs, and active efflux transport inhibit the entry of almost 98% of small molecules and 100% of macromolecules [117].”
BackgroundMoura, R. P., Almeida, A., & Sarmento, B. F. C. C. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.09.001 · Cited by 34
“lated drug and prolong the residence time in the body due to circumventing certain excretion mechanisms (Zhang et al., 2016).”
Farooq, M., Scalia, G., Umana, G. E., Parekh, U., Naeem, F., Abid, S., Khan, M., Zahra, S. G., Sarkar, H., & Chaurasia, B. K. (2023) · Brain Sciences · doi:10.3390/brainsci13121727 · Cited by 37
“Invasive injection, transient BBB disruption, and the use of drug delivery systems are approaches used to transport drugs to the brain [41].”
MethodHuang, T., Guo, Y., Wang, Z., Ma, J., Shi, X., Shen, M., & Peng, S. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c05831 · Cited by 31
A bioengineered drug-Eluting scaffold accelerated cutaneous wound healing In diabetic mice
Yin, H., Ding, G., Shi, X., Guo, W., Ni, Z., Fu, H. Y., & Fu, Z. (2016) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2016.04.056 · Cited by 31
Toxicity of nanostructured biomaterials
Tekade, R. K., Maheshwari, R., & Jain, N. K. (2017) · Elsevier eBooks · doi:10.1016/b978-0-08-100716-7.00027-1 · Cited by 30
Low-frequency HIFU induced cancer immunotherapy: tempting challenges and potential opportunities
Shi, G., Zhong, M., Ye, F., & Zhang, X. (2019) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2019.0232 · Cited by 31
Li, T., Liu, Y. Z., Bao, W., Luo, J., Gao, L., Chen, X., Wang, S., Yu, J., Ge, Y., Zhang, B., et al. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202100082 · Cited by 32
Regulation of Neurogenesis and Neuronal Differentiation by Natural Compounds
Chen, B., Yang, H., An, J., Tian, D., Guo, Y., & Yan, Y. (2021) · Current Stem Cell Research & Therapy · doi:10.2174/1574888x16666210907141447 · Cited by 34
Nanocarriers Call the Last Shot in the Treatment of Brain Cancers
Mehrabian, A., Mashreghi, M., Dadpour, S., Badiee, A., Arabi, L., Alavizadeh, S. H., Moosavian, S. A., & Jaafari, M. R. (2022) · Technology in Cancer Research & Treatment · doi:10.1177/15330338221080974 · Cited by 32
The exciting potential of nanotherapy in brain-tumor targeted drug delivery approaches
Agrahari, V. (2017) · Neural Regeneration Research · doi:10.4103/1673-5374.200796 · Cited by 30
“The transport mechanisms at the BBB can be subdivided into three major categories: passive diffusion; transporters mediated transcytosis (TMT); and fluid phase transport by vesicles (Meng et al., 2016; Zhang et al., 2016) ( Figure 1 ).”
Erişen, D. E., & Uludağ, K. (2024) · Advances in healthcare information systems and administration book series · doi:10.4018/979-8-3693-3661-8.ch010 · Cited by 29
Kim, K.-T., Lee, H. S., Lee, J.-J., Park, E. K., Lee, B.-S., Lee, J., & Bae, J. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0208 · Cited by 29
Nanoparticles and neurotoxicity: Dual response of glutamatergic receptors
Engin, A. B., & Engin, A. (2019) · Progress in brain research · doi:10.1016/bs.pbr.2019.03.005 · Cited by 31
Zhang, M., Cao, Q., Yuan, Y., Guo, X., Pan, D., Xie, R., Ju, X., Liu, Z., Wang, W., & Chu, L. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2023.108710 · Cited by 30
Varnamkhasti, B. S., Jafari, S., Taghavi, F., Alaei, L., Izadi, Z., Lotfabadi, A., Dehghanian, M., Jaymand, M., Derakhshankhah, H., & Saboury, A. A. (2020) · Current Drug Delivery · doi:10.2174/1567201817666200415111755 · Cited by 32
Powering up the molecular therapy of RNA interference by novel nanoparticles
Liao, W., Li, W., Zhang, T., Kirberger, M., Liu, J., Wang, P., Chen, W., & Wang, Y. (2016) · Biomaterials Science · doi:10.1039/c6bm00204h · Cited by 28
Self-citationDynamic nanoassemblies for imaging and therapy of neurological disorders
Zhang, L., Sun, H., Zhao, J., Lee, J., Low, L. E., Gong, L., Chen, Y., Wang, N., Zhu, C., Lin, P., et al. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113832 · Cited by 28
Solid-lipid nanoparticle formulation improves antiseizure action of cryptolepine
Mante, P. K., Adomako, N. O., Antwi, P., Kusi-Boadum, N. K., & Osafo, N. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111354 · Cited by 29
Kuo, Y., & Rajesh, R. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1621750 · Cited by 27
Small extracellular vesicles: a novel drug delivery system for neurodegenerative disorders
Pan, R., Chen, D., Hou, L., Hu, R., & Jiao, Z. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1184435 · Cited by 31
“However, almost all large molecule drugs and >98% of small molecule drugs have failed in hybridizing the BBB, with candidates exhibiting poor biopharmaceutical and pharmacokinetic properties (Zhang et al., 2016).”
BackgroundA narrative review of research progress on drug therapies for glioblastoma multiforme
Zheng, X., Tang, Q., Ren, L., Liu, J., Wan, L., Fu, W., Wang, J., & Du, G. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-8017 · Cited by 28
“The nanometer carrier used for drug loading has to meet the following conditions: (I) non-toxic, biodegradable and biocompatible; (II) particle size <100 nm; (III) stable in blood and not aggregated; (IV) evasive to phagocytes; (V) able to cross the BBB (through receptor-mediated vesicle trafficking); (VI) capable of…”
BackgroundNanotechnology in glioblastoma therapy: Advances in drug delivery systems and diagnostic approaches
Qindeel, M., Irfan, M., Ullah, S., Fathi‐karkan, S., Kharaba, Z. J., Rahdar, A., Aliahmad, M., & Aboudzadeh, M. A. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.106322 · Cited by 32
How to Develop Drug Delivery System Based on Carbohydrate Nanoparticles Targeted to Brain Tumors
Silant’ev, V. E., Shmelev, M. E., Belousov, A. S., Patlay, A. A., Shatilov, R. A., Farniev, V. M., & Kumeiko, V. V. (2023) · Polymers · doi:10.3390/polym15112516 · Cited by 30
Sonwani, A., Pathak, A., & Jain, K. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105855 · Cited by 28
Current development of nanocarrier delivery systems for Parkinson's disease pharmacotherapy
Kuo, Y., & Rajesh, R. (2018) · Journal of the Taiwan Institute of Chemical Engineers · doi:10.1016/j.jtice.2018.03.028 · Cited by 26
Jin, L. J., Nie, L., Deng, Y., Khana, G. J., & He, N. (2025) · Cell Proliferation · doi:10.1111/cpr.13804 · Cited by 26
“Moreover, polymeric nanoparticles have a prolonged half-life time, which can increase drug uptake by the CNS [32, 33].”
Zhang, M., Jiang, X., Zhang, Q., Zheng, T., Mohammadniaei, M., Wang, W., Shen, J., & Sun, Y. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202102274 · Cited by 25
Potential Role of Carbon Nanomaterials in the Treatment of Malignant Brain Gliomas
Caffo, M., Curcio, A., Rajiv, K., Caruso, G., Venza, M., & Germanò, A. (2023) · Cancers · doi:10.3390/cancers15092575 · Cited by 25
“After association between large molecules and theirs kindred receptors, they have shown transcytose transport via receptors [25].”
BackgroundLi, H., Zhang, X., Miao, J., Shi, Z. Y., Li, Z., Wen, M., Wang, L., Liang, J., Gao, J., Ye, Y., et al. (2023) · Chemical Engineering Journal · doi:10.1016/j.cej.2023.145413 · Cited by 24
Xiao, Y., Cheng, L., Xie, H., Ju, R.-J., Wang, X., Fu, M., Liu, J., & Li, X. (2018) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2018.1501377 · Cited by 24
“The barrier blocks over 98% small molecule drugs and almost 100% large molecule drugs such as recombinant proteins and monoclonal antibodies into brain [6].”
BackgroundDHA-PC protects kidneys against cisplatin-induced toxicity and its underlying mechanisms in mice
Shi, H.-H., Wang, C., Guo, Y., Xue, C., Zhang, T., & Wang, Y. (2019) · Food & Function · doi:10.1039/c8fo02386g · Cited by 23
Self-citationHan, Z., Yuan, M., Nguyen, N., Zhou, H.-C. “., Hubbard, J. E., & Wang, Y. (2024) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2024.215926 · Cited by 27
Zhu, J., Yi, X., Zhang, J., Chen, S., & Wu, Y. (2017) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2017.12.055 · Cited by 23
Revisiting gene delivery to the brain: silencing and editing
Conniot, J., Talebian, S., Simões, S. M. N., Ferreira, L., & Conde, J. (2021) · Biomaterials Science · doi:10.1039/d0bm01278e · Cited by 25
Mansour, A., Eldin, M. H., & El-sherbiny, I. M. (2025) · Journal of Materials Chemistry B · doi:10.1039/d4tb02428a · Cited by 23
“16,83 PD is irremediable and the available therapy is mainly palliative for both the motor and non-motor symptoms.”
Hosseini, L., Mahmoudi, J., Pashazadeh, F., Salehi‐Pourmehr, H., & Sadigh‐Eteghad, S. (2021) · Journal of Molecular Neuroscience · doi:10.1007/s12031-021-01842-6 · Cited by 24
“As demonstrated by the present review, treatment with NAD+ precursors restored NAD+ levels in the brain of rodent models of AD (Gong et al. 2013; Hou et al. 2018; Liu et al. 2013; Zhang et al. 2016).”
BackgroundResultInfluentialBrain safety concerns of nanomedicines: The need for a specific regulatory framework
Szabat-Iriaka, B., & Borgne, M. L. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.06.011 · Cited by 22
Governing transport principles for nanotherapeutic application in the brain
Helmbrecht, H., Joseph, A., McKenna, M., Zhang, M., & Nance, E. A. (2020) · Current Opinion in Chemical Engineering · doi:10.1016/j.coche.2020.08.010 · Cited by 24
“com and more widespread loss of barrier function 48 hours after injury [15].”
BackgroundActivatable luminescent probes for imaging brain diseases
Li, Z., Wang, C., Zhang, M., Li, S., Mao, Z., & Liu, Z. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101239 · Cited by 23
Theranostical application of nanomedicine for treating central nervous system disorders
Wang, R., & Xue, X. (2018) · Science China Life Sciences · doi:10.1007/s11427-017-9292-7 · Cited by 23
Central nervous system injury meets nanoceria: opportunities and challenges
Wang, Y., Zhang, M., He, J., Gong, M., Sun, J. H., & Yang, X. (2022) · Regenerative Biomaterials · doi:10.1093/rb/rbac037 · Cited by 21
“8 nm; thus, only particles sized 1 nm or less can be passively transported through ultrasmall pores [167].”
BackgroundWu, Y., Rakotoarisoa, M., Angelov, B., Deng, Y., & Angelova, A. (2022) · Nanomaterials · doi:10.3390/nano12132267 · Cited by 21
Wu, F., Wang, D.-D., Wen, M., Che, H.-X., Xue, C.-H., Yanagita, T., Zhang, T.-T., & Wang, Y.-M. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0623-2 · Cited by 20
“Moreover, DHA in the chemical form of lysophosphatidylcholine was uptake to brain by the primary transporter named MFSD2a across the blood-brain barrier [28, 29], and lyso-DHA-PC represented the major part of DHA supplementation in erythrocyte [30].”
Self-citationTranslational considerations for the design of untethered nanomaterials in human neural stimulation
Dominguez-Paredes, D., Jahanshahi, A., & Kozielski, K. (2021) · Brain stimulation · doi:10.1016/j.brs.2021.08.001 · Cited by 21
“, insulin, transferrin, antibodies, peptides) or chimeric molecules 428 [124-128].”
Dutra, J. A. P., Luiz, M. T., Tavares, A. G., Filippo, L. D. D., Carvalho, S. G., & Chorilli, M. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666220603152918 · Cited by 25
Nanotechnological Advancements in the Brain Tumor Therapy: a Novel Approach
Angolkar, M., Paramshetti, S., Halagali, P., Jain, V. K., Patil, A. B., & Somanna, P. (2022) · Therapeutic Delivery · doi:10.4155/tde-2022-0035 · Cited by 22
Chang, W. L. K., Chan, T. G., Raguseo, F., Mishra, A., Chattenton, D., de Rosales, R. T. M., Long, N. J., & Morse, S. V. (2023) · Scientific Reports · doi:10.1038/s41598-023-33671-5 · Cited by 24
Nanotechnology Meets Stem Cell Therapy for Treating Glioblastomas: A Review
Ghosh, A. K., Ghosh, A., & Das, P. K. (2024) · ACS Applied Nano Materials · doi:10.1021/acsanm.3c04714 · Cited by 22
Nabi, F., Arain, M. A., Hassan, M. F., Shah, Q. A., Almutairi, M. H., & Buzdar, J. A. (2024) · Journal of Comparative Physiology B · doi:10.1007/s00360-024-01578-w · Cited by 20
Dai, D., He, L., Chen, Y., & Zhang, C. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.12.013 · Cited by 21
Brain targeting of agomelatine egg lecithin based chitosan coated nanoemulsion
Shukr, M. H., & Ahmed-Farid, O. A.-H. (2021) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2021.1888980 · Cited by 21
“N) was 278.71% indicating increased drug brain targeting from optimized MNE either through olfactory pathway or through BBB after systemic absorption (Zhang et al. 2016).”
BackgroundInfluentialKassem, S. H., Arafa, M. M., Yehya, M. M., & Soliman, M. A. M. (2022) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-022-02219-1 · Cited by 21
A state-of-the-art liposome technology for glioblastoma treatment
Hasan, I., Roy, S., Ehexige, E., Wu, R., Chen, Y., Gao, Z., Guo, B., & Chang, C. (2023) · Nanoscale · doi:10.1039/d3nr04241c · Cited by 19
Bhatt, A., Bhardwaj, H., & Srivastava, P. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.07.019 · Cited by 23
Lorenzoni, R., Davies, S., Cordenonsi, L. M., Viçosa, J. A. D. S., Mezzomo, N. J., de Oliveira, A. L., do Carmo, G. M., Raffin, R. P., Alves, O. L., Vaucher, R. D. A., et al. (2020) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2020.105397 · Cited by 22
Gao, Y., Zhu, J., & Lu, H. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00873-7 · Cited by 20
“The TJs that limit the transport of molecules are a crucial characteristic of the BBB [3, 4].”
BackgroundPerspective on brain targeting drug delivery systems
Gao, H. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-814001-7.00018-4 · Cited by 19
Nanotechnology-enabled therapies improve blood-brain barrier challenges in brain tumor
Wenqi, Y., Lingxi, W., Mehmood, A., & Shah, W. (2023) · International Journal of Polymeric Materials · doi:10.1080/00914037.2023.2291105 · Cited by 24
“Various procedures have been explored to enhance BBB transport, including disruptive approaches like ultrasound, osmotic shock, and magnetic gradients [136] .”
InfluentialNasır, A., Rehman, M. U., Khan, T., Husn, M., Khan, M., Khan, A., Nuh, A. M., Jiang, W., Farooqi, H. M. U., & Bai, Q. (2024) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2024.2304814 · Cited by 18
“The small NPs have unique physiological properties like crossing the BBB and reaching the cells, which may facilitate nerve regeneration [156].”
Carnasciali, A., Amoriello, R., Bonechi, E., Mazzoni, A., Ravagli, C., Doumett, S., Cappiello, L., D’Elios, M. M., Baldi, G., & Ballerini, C. (2020) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-020-09931-w · Cited by 18
Nanotechnology‐empowered therapeutics targeting neurodegenerative diseases
Wang, Z., Gonzalez, K. M., Cordova, L. E., & Lu, J. (2023) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1907 · Cited by 19
Delivery of Fluorescent Nanoparticles to the Brain
Shimoni, O., Shi, B., Adlard, P. A., & Bush, A. I. (2016) · Journal of Molecular Neuroscience · doi:10.1007/s12031-016-0833-5 · Cited by 18
“However, the successful utilization of NPs for many central nervous system (CNS) applications requires an effective crossing of the blood-brain barrier (BBB) (Zhang et al. 2016).”
BackgroundHsing, M., Hsu, H., Chang, C.-H., Chang, K.-B., Cheng, C., Lee, J., Huang, C.-L., Yang, M., Yang, Y., Liu, S.-Y., et al. (2022) · Cells · doi:10.3390/cells11142172 · Cited by 19
“The drug carrier systems can specifically bind to the receptors of tumor cells to strengthen the efficacy of cytotoxicity [43].”
BackgroundEscalona-Rayo, O., Fuentes-Vázquez, P., Leyva‐Gómez, G., Cisneros, B., Villalobos, R., Magaña, J. J., & Quintanar‐Guerrero, D. (2017) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2017.1281949 · Cited by 17
Liu, S., Li, Y., Li, Z., Wu, S., Harrold, J. M., & Shah, D. K. (2024) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-024-09922-x · Cited by 17
“Moreover, the effective pore radius of brain tight junctions is less than 1 nm [78, 79], which is much smaller compared to other organs and restricts entry of most protein therapeutics.”
Wang, H.-Q., Liu, M., Wang, L. Y., Lan, F., Zhang, Y., Xia, J.-E., Xu, Z., & Zhang, H. (2020) · Phytomedicine · doi:10.1016/j.phymed.2020.153244 · Cited by 18
Engineered biomimetic drug-delivery systems for ischemic stroke therapy
Yang, Y., Yin, N., Gu, Z., Zhao, Y., Liu, C., Zhou, T., Zhang, K., Zhang, Z., Liu, J., & Shi, J. (2022) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2022.100129 · Cited by 17
Therapeutic ultrasound: The future of epilepsy surgery?
Bex, A., Bex, V., Carpentier, A. C., & Mathon, B. (2022) · Revue Neurologique · doi:10.1016/j.neurol.2022.03.015 · Cited by 18
Hui, Y., Zhao, H., Shi, L., & Zhang, H. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03788-6 · Cited by 17
Usman, F., Javed, I., Hussain, S. Z., Ranjha, N. M., & Hussaın, I. (2016) · RSC Advances · doi:10.1039/c6ra11799f · Cited by 16
Sharma, S., & Deep, S. (2024) · Chemical Communications · doi:10.1039/d4cc00822g · Cited by 16
Hyperglycemia-induced blood-brain barrier dysfunction: Mechanisms and therapeutic interventions
Chen, C., Xu, X., Lu, J., Xiang, Y., Shi, L., & Liu, D. (2025) · Microvascular Research · doi:10.1016/j.mvr.2025.104820 · Cited by 19
Sukumaran, S., Nair, K., & Velmurugan, R. (2020) · Journal of Pharmaceutical Negative Results · doi:10.4103/jpnr.jpnr_26_19 · Cited by 14
Agarwal, M., Sahoo, A. K., & Bose, B. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00480 · Cited by 14
Design and Fabrication of Brain-Targeted Drug Delivery
Soni, V., Pandey, V., Asati, S., Jain, P., & Tekade, R. K. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-817909-3.00014-5 · Cited by 18
Kirit, E., Gokce, C., Altun, B., & Yılmazer, A. (2025) · ACS Omega · doi:10.1021/acsomega.5c02206 · Cited by 17
Huang, T., Wu, J., Mu, J., & Gao, J. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00605 · Cited by 13
Development and evaluation of curcumin nano-niosomes for glioma-targeted therapy
Qian, H., Lv, J., & Xiu-ping, H. (2025) · Scientific Reports · doi:10.1038/s41598-025-95348-5 · Cited by 17
Targeted Delivery Platforms for the Treatment of Multiple Sclerosis
Jan, Z., Mollazadeh, S., Abnous, K., Taghdisi, S. M., Danesh, A., Ramezani, M., & Alibolandi, M. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00892 · Cited by 13
Synthesis of protein nanoparticles for drug delivery
Cheng, D., Yong, X., Zhu, T., Qiu, Y., Wang, J., Zhu, H. J., Ma, B., & Xie, J. (2016) · European Journal of BioMedical Research · doi:10.18088/ejbmr.2.2.2016.pp8-11 · Cited by 14
“These synthesized nanoparticles as drug delivery systems (DDS) have many advantages of high bioactivity efficacy, less side-effect for health tissues, long-acting time for its controllable release (10-12).”
BackgroundMartins, C., Chauhan, V. M., Abouselo, A., Alnatour, M., Aylott, J. W., & Sarmento, B. F. C. C. (2019) · Reaction Chemistry & Engineering · doi:10.1039/c9re00395a · Cited by 14
Nanocarriers based therapy and diagnosis of brain diseases: cross the blood-brain barrier
An, L., Zhang, J., Wang, X., Ge, Y., Sun, K., Dong, J., Wang, P., Li, W., Li, M., Hu, X., et al. (2025) · Science and Technology of Advanced Materials · doi:10.1080/14686996.2025.2554048 · Cited by 14
Self-citation
Metadata
- Authors
- Zhang, T.-T., Li, W., Meng, G., Wang, P., & Liao, W.
- Affiliations
- Department of Food Science and Technology
- IHRC
- Tongde Hospital of Zhejiang Province (CN)
- North Carolina Agricultural and Technical State University (US)
- South China University of Technology (CN)
- Corresponding author
- Liao, Wenzhen
- Venue
- Biomaterials Science
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2016
- Volume
- 4
- Issue
- 2
- Pages
- 219-229
- ISSN
- 2047-4830 (ISSN-L)
- 2047-4849
- OpenAlex
- W2190350005
- Cited by
- 308
- References
- 115
- Citations by year
- 2026: 6 · 2025: 35 · 2024: 40 · 2023: 31 · 2022: 33 · 2021: 33 · 2020: 41 · 2019: 21 · 2018: 23 · 2017: 24 · 2016: 21
- FWCI
- 1.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Biomaterials Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- blood-brain barrier, nanoparticles, brain drug delivery, central nervous system disorders, nanomedicine
- MeSH terms
- Biological Transport, Blood-Brain Barrier, Brain, Central Nervous System, Central Nervous System Diseases, Humans, Drug Delivery Systems, Nanotechnology, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.